BCL2L1 and cancer: The C‐terminal TM domain of Bcl‐xL specifically targets Bcl‐xL to the mitochondrial outer membrane,30 so Bcl‐xL translocates to the nucleus by an active mechanism through specific carriers in cancer cells.